[2024/10/18] Gene and Cell Therapy- weekly digest from PackGene

Oct 18, 2024

Featured

Oct 16 First clinical test of RNA editing restores missing protein in genetic disease, Wave says read more »
Oct 16 Gene Therapy Automatically Converts Omega-6 to Omega-3 Fatty Acids in the Body read more »
Oct 15 On Heels of Positive Parkinson's Gene Therapy Data, MeiraGTx Looks Ahead to Pivotal Test read more »
News
Oct 16 Study explores how traumatic brain injury may be linked to Alzheimer's disease read more »
Oct 16 Gene editing approach helps launch first-in-human clinical trial for rare genetic disease read more »
Oct 16 ARTHEx Biotech Announces Publication of Promising Preclinical Research for Myotonic Dystrophy Type 1 (DM1) read more »
Oct 15 GSK sues Moderna over mRNA vaccine patents, seeks 'reasonable royalty' read more »
Oct 14 Improving the recipe for gene therapy: New treatment for Gaucher disease shows promise read more »
Oct 10 Diverse Genomes Make Medicine More Equitable read more »
Articles
Oct 16 Suppression of CNS APOE4 Expression by miRNAs Delivered by the S2 AAVrh.10 Capsid-Modified AAV Vector read more »
Oct 16 Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR–Cas9 ribonucleoprotein read more »
Oct 11 Model-directed generation of artificial CRISPR–Cas13a guide RNA sequences improves nucleic acid detection read more »
Oct 08 Systemic gene therapy corrects the neurological phenotype in a mouse model of NGLY1 deficiency read more »
Oct 01 Multi-species genome-wide CRISPR screens identify conserved suppressors of cold-induced cell death read more »

PackGene’s Newsletter

Receive the latest news and insights to your inbox.

Subscribe Now
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

AAV Packaging Services

We have developed a series of proprietary technologies that greatly improve AAV production outcomes including titer, purity, potency, and consistency.

READ MORE

Off-the-Shelf AAV Products

We offer a library of carefully designed and pre-stocked AAV vectors for a wide variety of experimental needs.

READ MORE